News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News ACC 2025 STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients L.A. McKeown March 29, 2025
News Conference News ACC 2022 Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD L.A. McKeown April 04, 2022
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2021 SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal L.A. McKeown May 16, 2021
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
Presentation ACC 2018 A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial) Presenter: Mehdi H. Shishehbor March 12, 2018
News Conference News ACC 2018 COMPASS Approach Helps With Leg Complications in Patients With PAD Todd Neale March 12, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2015 ERICCA: Remote Ischemic Preconditioning Fails to Improve Long-Term Outcomes After CABG Yael L. Maxwell March 16, 2015
News Conference News ACC 2015 Study EMBRACEs Novel Drug, But Fails to Reduce Infarct Size in Anterior STEMI Yael L. Maxwell March 15, 2015